Abstract:e13002 Background: Next generation sequencing (NGS) technologies have already shown numerous advances to revolutionize our understanding of cancer genomic profiling and improve cancer treatments. There have been many NGS data analysis tools available for identification of different genomic alternations including short insertion and deletion (short indel, < 25 bp in general). However, detection of > 100 bp large indel (L-indel) from short reads (generally < 200 bp) remains a huge challenge. L-indels identified in genes like MET and FLT3 have proven a critical implication in cancer treatments. Moreover, there is an urgent need for an algorithm to validate L-indels generated by genomic modification systems like ZFN, TALENs and CRISPR/Cas9. Methods: A novel algorithm was developed for calling L-indels in targeted sequencing data as following: raw reads were first filtered by selecting high-quality ones and correcting wrong bases; a chunk of contig (unitig) was then assembled and aligned to reference genome; lastly, break point information was collected and L-indels were calculated. The algorithm was applied on the reads generated from NA12878 cell line and FFPE samples collected in our lab respectively on the Illumina platform. Validation were performed by PCR and Sanger sequencing. Results: 22 novel exonic L-indels (17 deletions and 5 insertions) were identified with a median size of 1,616 bp (range: 25-6,684 bp) from NA12878 sequencing data and 100% successfully confirmed by Sanger sequencing. In addition, 6 out of 9 reported L-indels were also found with the rest awaiting for further exploration. Strikingly, a 2,446 bp deletion on MSH6, encodes an important component in mismatch repair (MMR) system, was detected on a FFPE sample of a lung cancer adenocarcinoma, which prompted to consideration of MMR deficiency otherwise. Conclusions: We have developed and validated a novel and accurate method for NGS large indels detection dedicated for targeted sequencing data in clinical cancer setting. Equipment of this method will greatly increase the capability of comprehensively understanding genomic alterations from a single NGS-based assay, and provide more information for potential clinical use.

Improved NGS variant calling tool for the PRSS1–PRSS2 locus

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

A Novel Approach to Detect Large Indels from Targeted Sequencing Data in Clinical Cancer Setting

Long-read nanopore sequencing enables accurate confirmation of a recurrent PMS2 insertion-deletion variant located in a region of complex genomic architecture

Identification of Novel SNPs by Next-Generation Sequencing of the Genomic Region Containing Theapcgene in Colorectal Cancer Patients in China

Benchmarking variant callers in next-generation and third-generation sequencing analysis

Identification of synonymous pathogenic variants in monogenic disorders by integrating exome with transcriptome sequencing

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

Evaluation of false positive and false negative errors in targeted next generation sequencing

PSAP‐Genomic‐Regions: A Method Leveraging Population Data to Prioritize Coding and Non‐Coding Variants in Whole Genome Sequencing for Rare Disease Diagnosis

PSAP-genomic-regions: a method leveraging population data to prioritize coding and non-coding variants in whole genome sequencing for rare disease diagnosis

A Remark on Copy Number Variation Detection Methods

Enhancing Variant Calling in Whole-Exome Sequencing Data Using Population-Matched Reference Genomes.

A comprehensive assessment of Next-Generation Sequencing variants validation using a secondary technology.

Characterizing the Genetic Polymorphisms in 370 Challenging Medically Relevant Genes Using Long-Read Sequencing Data from 41 Human Individuals among 19 Global Populations

Enhancing SNV identification in whole-genome sequencing data through the incorporation of known genetic variants into the minimap2 index

An Exome Sequencing Pipeline for Identifying and Genotyping Common CNVs Associated with Disease with Application to Psoriasis

High-throughput Screening of Prostate Cancer Risk Loci by Single Nucleotide Polymorphisms Sequencing.

The benefit of a complete reference genome for cancer structural variant analysis

Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads